constant
threat
diseasecaus
microorgan
seriou
concern
evok
paradigm
shift
pharmaceut
biotechnolog
industri
prompt
exploit
heterolog
express
compound
live
system
plant
occupi
import
posit
current
short
list
biofactori
promis
rapid
develop
field
plantderiv
biopharmaceut
agent
edibl
vaccin
simpl
conveni
approach
involv
high
yield
protein
lower
product
storag
cost
elimin
pathogen
contamin
littl
process
requir
secur
deliveri
oral
vaccin
predomin
benefit
boost
use
system
recent
year
howev
certain
limit
often
reduc
express
target
gene
plant
system
encourag
research
comprehens
investig
heterolog
protein
express
plant
develop
novel
strategi
ensur
suffici
express
biopharmaceut
peptid
induc
immun
respons
pharmaceut
protein
nvcp
produc
use
heterolog
system
exampl
bacteria
yeast
mous
embryo
cell
spodoptera
frugiperda
cell
babi
hamster
kidney
cell
hybridoma
clone
differ
level
express
recombin
protein
express
produc
photosyntheticallyact
organ
plant
chlamydomona
reinhardtii
use
differ
organ
plant
like
leav
seed
tuber
tape
root
merlin
et
al
plant
maintain
strong
posit
among
heterolog
protein
product
biofactori
mani
advantag
system
import
benefit
use
plant
biofactori
includ
eas
growth
rel
low
water
usag
lower
storag
cost
requir
miner
grow
adapt
cell
cultur
agricultur
product
lack
pathogen
contamin
highli
scalabl
product
system
plant
also
posttransl
modifi
express
protein
correctli
allow
proper
function
lossl
wahe
escherichia
coli
inappropri
express
antigen
protein
lack
capac
varieti
posttransl
modif
fold
requir
yeast
insect
cell
line
perform
essenti
posttransl
modif
immunologicallysignific
differ
modif
limit
use
system
express
platform
vaccin
develop
houdebin
tabl
differ
express
system
use
produc
heterolog
protein
compar
notabl
advantag
limit
specifi
import
viral
diseas
caus
signific
death
pandem
human
popul
influenza
measl
hepat
b
hepat
c
hepat
e
human
immunodefici
viru
acquir
immunodefici
syndrom
hivaid
human
papilloma
viru
hpv
infect
rabi
wherea
consider
econom
loss
anim
attribut
avian
influenza
norwalk
viru
foot
mouth
diseas
cholera
tuberculosi
diphtheria
among
bacteri
diseas
caus
consider
loss
life
plant
use
express
system
produc
vaccin
pharmaceut
use
prophylact
cur
agent
diseas
biopharmaceut
recent
produc
plant
import
viral
bacteri
protozoan
diseas
cancer
list
tabl
sever
plant
transient
express
reli
viral
vector
system
scientist
use
agrobacterium
transient
express
plant
reli
viral
vector
kapila
et
al
studi
plant
virus
reveal
latent
abil
carri
foreign
gene
discoveri
positivesens
rna
virus
tmv
tobacco
rattl
viru
trv
potato
viru
x
pvx
facilit
use
heterolog
protein
express
vector
hefferon
viral
vector
classifi
differ
way
accord
purpos
serv
two
main
group
independ
viral
vector
ii
minim
viral
vector
independ
viral
vector
replic
inocul
plant
viral
particl
multipli
site
infect
move
system
virusencod
particl
infect
maximum
plant
tissu
minim
vector
contrast
replic
lack
system
movement
modifi
achiev
greater
protein
express
although
discoveri
plant
virus
use
vector
mileston
product
recombin
protein
inabl
carri
larg
construct
hinder
develop
optim
much
need
modif
limit
address
develop
magnifect
technolog
gleba
et
al
agrobacterium
use
system
movement
agent
deliv
viral
replicon
plant
produc
high
yield
recombin
protein
strategi
combin
benefit
three
system
dna
deliveri
capac
agrobacterium
express
level
rna
virus
posttransl
modif
low
product
cost
plant
magnifect
technolog
mani
benefit
includ
eas
biocontain
transgen
simpl
scaleup
highlevel
express
heterolog
protein
low
cost
versatil
protein
express
singlechain
antibodi
antigen
enzym
etc
howev
still
limit
capac
posttransl
modifi
recombin
protein
particular
aberr
glycosyl
pattern
make
recombin
protein
nonfunct
affect
immunogen
case
vaccin
gleba
et
al
high
express
level
recombin
protein
also
lethal
effect
plant
hepat
b
viru
hbv
surfac
antigen
hbsag
gleba
et
al
mostli
cell
expans
cell
divis
product
immunoglobulin
g
igg
antibodi
magnifect
also
difficult
requir
manipul
viral
vector
recent
modif
gener
magnicon
trade
name
magnifect
allow
express
mani
import
biopharmaceut
product
import
diseas
includ
malaria
use
deconstruct
viral
vector
et
al
b
exampl
magnicon
system
modifi
form
use
includ
product
follicular
nonhodgkin
lymphoma
yusibov
et
al
e
coli
heatlabil
enterotoxin
b
ltb
rosalesmendoza
et
al
viruslik
particl
develop
anoth
import
techniqu
high
protein
express
exampl
chimer
cucumb
mosaic
virus
cmv
hepat
c
viru
nuzzaci
et
al
pvx
use
express
hpv
cerovska
et
al
shortcom
magnicon
system
address
construct
peaq
vector
system
peaq
special
type
nonrepl
vector
base
cowpea
mosaic
viru
cpmv
system
provid
high
recombin
protein
express
without
fear
biocontamin
genet
drift
peyret
lomonossoff
new
express
system
base
delet
version
cpmv
mutat
region
utr
enhanc
express
green
fluoresc
protein
gfp
dsred
hbv
core
antigen
hbcag
human
antihiv
antibodi
sainsburi
lomonossoff
joensuu
et
al
enhanc
heterolog
protein
product
plant
scientist
modifi
strategi
use
express
vector
deriv
viru
origin
util
report
gene
gu
gfp
includ
plantbas
intron
proper
express
eukaryot
cell
canizar
et
al
lico
et
al
marillonnet
et
al
minim
pvx
vector
sole
rna
polymeras
gene
prove
effect
express
gu
protein
yield
util
full
length
pvx
vector
larsen
curti
posttranscript
gene
silenc
express
minim
pvx
fragment
coexpress
solanacea
base
viral
vector
viral
protein
tomato
bushi
stunt
viru
hcpro
viral
protein
tobacco
etch
furthermor
enhanc
express
protein
attain
use
major
sequenc
cpmv
non
replic
viral
vector
canizar
et
al
use
hairi
root
protein
express
system
trv
vector
exhibit
higher
express
protein
accumul
pvx
base
vector
larsen
curti
number
strategi
use
introduc
foreign
gene
cmvbase
system
cmvbase
induc
vector
cmvbase
advanc
replic
vector
includ
manipul
clone
site
easi
use
also
reassort
genotyp
taken
consider
delet
cmv
movement
protein
also
lead
greater
protein
accumul
nicotiana
benthamiana
suitabl
host
recombin
protein
product
use
agroinfiltr
wide
host
rang
cmv
particular
edg
vector
choic
variou
plant
use
recombin
protein
factori
hwang
et
al
hydrophobin
sequenc
trichoderma
reesei
fuse
gfp
infiltr
agrobacterium
transient
express
n
benthamiana
report
enhanc
accumul
gfp
concentr
fusion
protein
reach
total
solubl
protein
delay
necrosi
infiltr
leav
joensuu
et
al
interestingli
fusion
target
endoplasm
reticulum
er
produc
larg
novel
protein
bodi
allow
recoveri
fusion
protein
extract
simpl
scalabl
recoveri
process
base
aqueou
twophas
system
singlestep
phase
separ
select
recov
account
mgml
fusion
increas
express
recombin
protein
also
provid
easi
method
subsequ
purif
fusion
technolog
combin
speed
posttransl
modif
capac
plant
increas
valu
transient
plantbas
system
joensuu
et
al
furthermor
lower
express
desir
gene
challeng
weak
promot
plant
optim
gener
synthet
promot
review
liu
et
al
technolog
describ
liu
et
al
util
improv
therapeut
protein
express
plant
achiev
desir
result
develop
transient
express
improv
molecular
bioinformat
analysi
sequenc
enabl
manipul
synthet
enhanc
suppressor
transcript
factor
bind
domain
promot
sainsburi
lomonossoff
studi
suggest
still
much
done
improv
express
heterolog
protein
plant
involv
optim
vector
system
necessari
find
region
vector
system
affect
innat
abil
replic
way
suppress
transgen
silenc
interest
review
alba
et
al
cover
sever
gene
silenc
pathway
plant
de
alba
et
al
improv
nonrepl
viral
system
reli
hypertransl
rather
replic
peaq
vector
system
key
event
develop
plantderiv
biopharmaceut
summar
briefli
fig
momentum
use
plant
biofactori
increas
first
vaccinerel
protein
express
transgen
tobacco
plant
hiatt
et
al
decad
develop
number
breakthrough
occur
particular
express
hbsag
tobacco
plant
mason
et
al
follow
present
malari
parasit
epitop
turpen
et
al
heatlabil
enterotoxin
b
ltb
produc
potato
plant
haq
et
al
function
express
e
coli
first
human
phase
clinic
trial
plantderiv
ltb
pave
way
design
product
edibl
vaccin
rigano
et
al
lowlevel
express
recombin
protein
hinder
develop
excit
field
anthrax
antigen
express
chloroplastbas
system
success
use
immun
mice
koya
et
al
time
magnifect
technolog
introduc
enhanc
heterolog
protein
express
gleba
et
al
technolog
import
breakthrough
increas
recombin
protein
express
sever
modif
report
subsequ
year
singl
intranas
dose
plantderiv
vaccin
produc
tobacco
effici
activ
cell
antibodi
tetanu
toxin
mice
tregon
et
al
progress
field
continu
report
plantbas
epitop
present
cottontail
rabbit
papilloma
viru
immun
rabbit
confirm
efficaci
plantderiv
hpv
vaccin
kohl
et
al
later
first
plantderiv
vaccin
approv
immun
chicken
newcastl
diseas
viru
miller
et
al
first
phase
ii
clinic
trial
plantderiv
therapeut
compound
suspens
cultur
carrot
cell
direct
gaucher
diseas
undertaken
rigano
et
al
first
phase
human
clinic
trial
antiidiotyp
vaccin
nonhodgkin
lymphoma
perform
mccormick
et
al
first
preclin
clinic
trial
viruslik
particl
vlp
influenza
first
phase
ii
clinic
trial
carorx
plantderiv
antibodi
dental
decay
undertaken
rigano
et
al
fda
approv
phase
ii
human
clinic
trial
vlp
laanger
plant
provid
vaccin
therapeut
compound
number
way
includ
cell
root
cultur
greenhous
field
low
product
heterolog
protein
hinder
commerci
plantmad
biopharmaceut
product
long
time
recent
develop
increas
heterolog
protein
express
plant
variou
novel
techniqu
includ
magnifect
optim
made
commerci
possibl
plant
viral
vector
combin
provid
new
way
increas
recombin
protein
product
improv
bioprocess
number
factor
must
consid
recombin
protein
express
codon
optim
organel
organspecif
express
proteas
etc
extens
review
elsewher
world
threaten
influenza
pandem
situat
plant
provid
quick
reliabl
vaccin
product
system
major
hurdl
remain
glycosyl
pathway
plant
highli
resist
chang
posttranscript
modif
recombin
protein
human
anim
remain
limit
overcom
instal
novel
glycosyl
pathway
plant
instal
novel
pathway
achiev
arabidopsi
thaliana
photorespir
suppress
pathway
instal
increas
biomass
product
novel
technolog
use
overcom
health
concern
provid
cheaper
medicin
thirdworld
countri
diseas
burden
high
therefor
time
govern
commerci
enterpris
alloc
fund
research
plantmad
vaccin
therapeut
agent
commerci
